X4 Pharmaceuticals, INC

X4 Pharmaceuticals has appointed Kelly Gold, an experienced CFO, to its Board of Directors, effective July 1, 2026, to enhance strategic and financial expertise.

X4 Pharmaceuticals filed an amendment to its 8-K to correct a typographical error regarding a director nominee.

X4 Pharmaceuticals, Inc. announced the results of its annual stockholder meeting, including the election of directors, ratification of its auditor, and approval of an amended equity incentive plan.

X4 Pharmaceuticals announced Q3 2025 financial results, a strategic shift to chronic neutropenia, significant cost savings, and extended cash runway.

X4 Pharmaceuticals successfully completed a public offering of common stock and pre-funded warrants, raising approximately $145.6 million to fund its operations.

X4 Pharmaceuticals announced a strategic restructuring, including a 50% workforce reduction, to sharpen operational focus and align resources with its long-term strategy.

X4 Pharmaceuticals reports a significant decrease in revenue and an increased net loss for Q1 2026, primarily due to the cessation of substantial upfront license revenue recognized in the prior year.

X4 Pharmaceuticals reports Q3 2025 results, detailing a strategic shift to chronic neutropenia, significant workforce reductions, and successful capital raises totaling over $226 million.

X4 Pharmaceuticals reported a significant net loss in Q2 2025, driven by operating expenses and the absence of a prior year asset sale, while also raising substantial doubt about its ability to continue as a going concern.

X4 Pharmaceuticals announces Q1 2025 financial results, marked by revenue from the Norgine agreement and strategic restructuring efforts to focus on chronic neutropenia.

X4 Pharmaceuticals reports its Q3 2024 results, including initial revenue from XOLREMDI sales and continued progress in clinical trials for chronic neutropenia.

X4 Pharmaceuticals reports a net income of $90.8 million for the second quarter of 2024, primarily driven by a $105 million gain from the sale of a Priority Review Voucher.

X4 Pharmaceuticals details a strategic pivot towards chronic neutropenia, significant capital raises, and management changes in its 2025 annual report.

X4 Pharmaceuticals details its 2024 financial performance and announces a strategic restructuring to prioritize mavorixafor development and optimize XOLREMDI commercialization.

X4 Pharmaceuticals is seeking FDA approval for mavorixafor to treat WHIM syndrome, with a potential launch in the second quarter of 2024.

X4 Pharmaceuticals CFO David Kirske sold 8,543 shares of common stock for tax obligations.

X4 Pharmaceuticals reports that Director Kelly Gold was granted 110,000 stock options with an exercise price of $4.085.

X4 Pharmaceuticals CFO David Kirske reported a sale of 16,961 common shares on May 12, 2026, for tax obligations.

X4 Pharmaceuticals, Inc. Director Gary Bridger was granted 110,000 stock options with an exercise price of $4, vesting upon shareholder approval.

X4 Pharmaceuticals director Francoise de Craecker was granted 110,000 stock options with a $4 exercise price, vesting upon 2026 stockholder approval.

X4 Pharmaceuticals director Michael S. Wyzga was granted 110,000 stock options with a $4 exercise price, vesting upon 2026 stockholder approval.

X4 Pharmaceuticals, Inc. announces its 2026 Annual Meeting of Stockholders to vote on director elections, auditor ratification, an expanded equity incentive plan, and executive compensation.

X4 Pharmaceuticals has filed a definitive proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934.

X4 Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held on June 9, 2025, to elect a director, ratify the selection of an independent accounting firm, and conduct a non-binding advisory vote on executive compensation.

X4 Pharmaceuticals is seeking stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and potentially attract a broader range of investors.

X4 Pharmaceuticals has filed a definitive proxy statement related to its upcoming shareholder meeting.

X4 Pharmaceuticals will hold its annual stockholders meeting on June 10, 2024, to elect directors, ratify the selection of its accounting firm, and conduct a say-on-pay vote.

Growth Equity Opportunities 18 VGE, LLC and affiliated NEA entities increased their beneficial ownership in X4 Pharmaceuticals, Inc. to 6.2% following participation in a recent underwritten offering.

Coastlands Capital and related entities report a 9.99% beneficial ownership in X4 Pharmaceuticals following a recent private placement.

Growth Equity Opportunities 18 VGE, an affiliate of New Enterprise Associates, increased its beneficial ownership in X4 Pharmaceuticals, Inc. to 9.99% through a recent private placement.

Bain Capital Life Sciences entities have significantly increased their beneficial ownership in X4 Pharmaceuticals to 9.99% following a new financing round and concurrent executive leadership changes.

Perceptive Advisors LLC and Joseph Edelman have reported a 7.3% beneficial ownership stake in X4 Pharmaceuticals, Inc. via a Schedule 13G filing.

Morgan Stanley and its investment management arm, along with Inception Trust, have disclosed significant beneficial ownership in X4 Pharmaceuticals, Inc.

Saturn V Capital Management LP and Xiaoying Tian have reported a 7.36% beneficial ownership stake in X4 Pharmaceuticals, Inc. common stock.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 2.80% beneficial ownership stake in X4 Pharmaceuticals, Inc. as of December 31, 2025.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have reported a beneficial ownership of 9.4% in X4 Pharmaceuticals, Inc. common stock.

FMR LLC and Abigail P. Johnson have reported a 9.7% beneficial ownership stake in X4 Pharmaceuticals, Inc. common stock.